Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
MS Focus At Sea
MS Focus At Sea offers educational programs, opportunities to meet old and new friends, and adventures for every...
/Events/MSF-Events/MSFocus-Cruise-For-A-Cause
Cooling Program
The Cooling Program offers a variety of items, free of charge, to help individuals with MS...
/Get-Help/MSF-Programs-Grants/Cooling-Program
Shop
Privacy
Terms of Use
Site Map
Study: Extending dosing intervals reduces deadly side effect risk from MS drug
February 07, 2018
According to a new study led by MS specialists at NYU Langone Health, a commonly-prescribed multiple sclerosis infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended. The findings showed that extending dosing of natalizumab from every four weeks to every five to 12 weeks significantly reduced the risk of developing a rare but potentially fatal brain infection called progressive multifocal leukoencephalopathy. The findings could influence how neurologists prescribe the medication.
Natalizumab, a monoclonal antibody, is used to prevent MS relapses, improve quality of life, and slow worsening disability. The medication is indicated to be prescribed in 300-milligram infusion doses every four weeks. Taking the medication longer than two years, however, may increase risk PML, which is caused by the John Cunningham virus. There have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab. Patients who test JCV antibody-positive are typically either told to not to start natalizumab, or have had treatment stopped after two years, when risk was deemed to be too high. The new study, however, reports safety data through up to six years, when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent.
Researchers reviewed data on all patients who have been exposed to JCV who are enrolled in TOUCH, the U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy program for natalizumab that requires manufacturers to document all uses of a medication to ensure that the benefits of a drug outweigh its risks. Because the optimal extended dose schedule is not known, researchers chose to look at the data in multiple ways: with the primary definition looking at extended dose history in the last 18 months, the secondary definition looking at extended dose occurring at any time in the dosing history, and for tertiary definition looking primarily at how extended dose history affects PML risk. The results showed clinically and statistically significant risk reductions with all definitions.
The new study did not look at drug efficacy comparing extended to standard doses. However, previous research found extending the dose up to eight weeks did not negatively affect the medication's efficacy in a retrospective sample of 2,000 people. The authors are planning prospective efficacy studies of extended dose natalizumab.
Natalizumab is manufactured by Biogen Idec and Elan, and sold under the name Tysabri®. Biogen provided the researchers access to their data and statistical support.
The authors presented their findings at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2018 in San Diego.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more